Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis.

UNLABELLED Incidence studies of primary sclerosing cholangitis (PSC) are important for describing the disease's burden and for shedding light on the disease's etiology. The purposes of this study were to conduct a systematic review of the incidence studies of PSC with a meta-analysis and to investigate possible geographic variations and temporal trends in the incidence of the disease. A systematic literature search of MEDLINE (1950-2010) and Embase (1980-2010) was conducted to identify studies investigating the incidence of PSC. The incidence of PSC was summarized with an incidence rate (IR) and 95% confidence intervals. The test of heterogeneity was performed with the Q statistic. Secondary variables extracted from the articles included the following: the method of case ascertainment, the country, the time period, the age, the male/female incidence rate ratio (IRR), and the incidence of PSC subtypes (small-duct or large-duct PSC and inflammatory bowel disease). Stratified and sensitivity analyses were performed to explore heterogeneity between studies and to assess effects of study quality. Time trends were used to explore differences in the incidence across time. The search retrieved 1669 potentially eligible citations; 8 studies met the inclusion criteria. According to a random-effects model, the pooled IR was 0.77 (0.45-1.09) per 100,000 person-years. However, significant heterogeneity was observed between studies (P < 0.001). Sensitivity analyses excluding non-population-based studies increased the overall IR to 1.00 (0.82-1.17) and eliminated the heterogeneity between studies (P = 0.08). The IRR for males versus females was 1.70 (1.34-2.07), and the median age was 41 years (35-47 years). All studies investigating time trends reported an overall increase in the incidence of PSC. CONCLUSION The incidence of PSC is similar in North American and European countries and continues to increase over time. Incidence data from developing countries are lacking, and this limits our understanding of the global incidence of PSC.

[1]  James H. Lewis,et al.  Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease , 2010, Digestive Diseases.

[2]  E. Björnsson,et al.  Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in sweden , 2010, Hepatology.

[3]  A. Bitton,et al.  Epidemiology of Crohn's Disease in QuéBec, Canada , 2009, Inflammatory bowel diseases.

[4]  T. Miloh,et al.  A retrospective single-center review of primary sclerosing cholangitis in children. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  F. Gordon.  Primary sclerosing cholangitis. , 2008, The Surgical clinics of North America.

[6]  A. Dusak,et al.  MRCP vs ERCP in the evaluation of biliary pathologies: Review of current literature , 2008, Journal of digestive diseases.

[7]  K. Lindor,et al.  Primary sclerosing cholangitis. , 2008, Hepatology.

[8]  M. Solaymani-Dodaran,et al.  Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. , 2008, Journal of hepatology.

[9]  R. Chapman,et al.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[10]  G. Kaplan,et al.  The Burden of Large and Small Duct Primary Sclerosing Cholangitis in Adults and Children: A Population-Based Analysis , 2007, The American Journal of Gastroenterology.

[11]  G. Gores,et al.  Primary sclerosing cholangitis: Summary of a workshop , 2006, Hepatology.

[12]  Mieke Koehoorn,et al.  The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study , 2006, The American Journal of Gastroenterology.

[13]  P. Munkholm,et al.  Increasing Incidences of Inflammatory Bowel Disease and Decreasing Surgery Rates in Copenhagen City and County, 2003–2005: A Population-Based Study from the Danish Crohn Colitis Database , 2006, The American Journal of Gastroenterology.

[14]  Jack Satsangi,et al.  New genes in inflammatory bowel disease: lessons for complex diseases? , 2006, The Lancet.

[15]  N. Nikolaidis,et al.  Small-Duct Primary Sclerosing Cholangitis. A Single-Center Seven-Year Experience , 2005, Digestive Diseases and Sciences.

[16]  A. Zinsmeister,et al.  PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis , 2004, Gut.

[17]  M. Gravenor,et al.  Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. , 2004, Gastroenterology.

[18]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[19]  T. Therneau,et al.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. , 2003, Gastroenterology.

[20]  E Keller,et al.  Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. , 2002, Endoscopy.

[21]  K. Boberg,et al.  Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis , 2002, Gut.

[22]  B. McMahon,et al.  Prevalence of autoimmune liver disease in Alaska natives , 2002, American Journal of Gastroenterology.

[23]  J. Talwalkar,et al.  Primary sclerosing cholangitis. , 2002, Seminars in gastrointestinal disease.

[24]  S. Targan,et al.  Biologic therapy of inflammatory bowel disease. , 2002, Gastroenterology.

[25]  K. Boberg,et al.  Epidemiology of primary sclerosing cholangitis. , 2001, Best practice & research. Clinical gastroenterology.

[26]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[27]  A. Sanyal,et al.  Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study. , 2000, Radiology.

[28]  J. Ebbesen,et al.  [Incidence and prevalence of autoimmune liver diseases]. , 1998, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[29]  H T Sørensen,et al.  Change in incidence of Crohn's disease and ulcerative colitis in Denmark. A study based on the National Registry of Patients, 1981-1992. , 1997, International journal of epidemiology.

[30]  J. Lennard-jones,et al.  Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). , 1996, Gut.

[31]  Y. Chawla,et al.  Primary sclerosing cholangitis: An experience from India , 1996, Journal of gastroenterology and hepatology.

[32]  A. Yokota,et al.  Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. , 1995, Journal of gastroenterology.

[33]  D. Palli,et al.  Epidemiology of inflammatory bowel disease over a 10-year period in Florence (1978-1987). , 1991, The Italian journal of gastroenterology.

[34]  G. Porro,et al.  Biologic Therapy for Inflammatory Bowel Disease , 2012, Drugs.

[35]  E. Ierardi,et al.  Onset of Liver Damage after a Single Administration of Infliximab in a Patient with Refractory Ulcerative Colitis , 2006, Clinical drug investigation.

[36]  E. Kaltenthaler,et al.  MRCP compared to diagnostic ERCP for diagnosis when biliary obstruction is suspected: a systematic review , 2006, BMC Medical Imaging.

[37]  S. Hanauer.  Evolutionary biologic therapy for inflammatory bowel disease , 1999, Current gastroenterology reports.

[38]  K. Boberg,et al.  Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. , 1998, Scandinavian journal of gastroenterology.

[39]  A. Parés,et al.  Epidemiology of primary sclerosing cholangitis in Spain , 1994 .